>2X}B6R^_/B:]*KR?13CM*=@;LGDXAS(N{S=U/4
SYSTEM PROCESSING...
>2X}B6R^_/B:]*KR?13CM*=@;LGDXAS(N{S=U/4
SYSTEM PROCESSING...
Posted: 2025-04-14 10:53:41 UTC
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
This article contains some claims that remain unverified. While much of the content may be accurate, exercise care when relying on this information.
Status
Last Updated
2025-04-14 10:53:56 UTC
Verified By
Rollup News
The article discusses the need for a new patent strategy for therapeutic monoclonal antibodies due to the Amgen v. Sanofi case, which invalidated broad functional claims for antibody genera in the USA.
Patent protection for therapeutic monoclonal antibodies
Impact of Amgen v. Sanofi case
Invalidation of broad functional claims
Need for a fundamental shift in patent strategy
Broad functional claims for antibody genera are no longer valid in the USA
Developing a new patent strategy to protect therapeutic monoclonal antibodies